logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Syndax and Incyte Traded UP in Today’s Early Morning  

Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals ( SNDX ) and Incyte ( INCY ) announced positive data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease ( GVHD ) following...

Read More

July 24, 2023

0

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

Merck and Moderna Inc Announcement Merck ( MRK ) and Moderna Inc ( MRNA )  announced the initiation of the pivotal Phase 3 randomized V940-001clinical trial evaluating V940 ( mRNA- 4157 ), an investigational individualized neoantigen therapy ( INT ),...

Read More

July 26, 2023

0

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen ( IMGN ) , a leader in the expanding field of antibody-drug conjugates ( ADCs ) for the treatment of cancer, today reviewed recent progress in the business and...

Read More

July 31, 2023

0

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live Audio Website at 4.30 PM  TODAY CymaBay Therapeutics, Inc. ( CBAY ) - a clinical-stage biopharmaceutical company developing therapies for liver and other chronic...

Read More

August 10, 2023

0

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals ( REGN ) announced that the U.S. FDA has approved EYLEA HD ( aflibercept ) Injection 8 mg for the treatment of patients with wet age-related macular degeneration ( wAMD ),...

Read More

August 21, 2023

0

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

Arcus Biosciences Arcus Biosciences ( RCUS ) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer and chronic inflammatory diseases, and other diseases. In partnership with firms and physicians around the world, Arcus...

Read More

August 23, 2023

0

Halozyme Therapeutics ENHANZE Reduces Roche's Tecentriq® Treatment Time to 7 Minutes from 30-60

Halozyme Therapeutics in the NEWS Halozyme Therapeutics ( HALO ) announced today that the Medicines and Healthcare Products Regulatory Agency ( MHRA ) in Great Britain has approved Roche's ( RHBBY ) subcutaneous Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug...

Read More

August 29, 2023

0

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly 

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals ( CRNX ) announced that its oral and once daily investigational compound paltusotine achieved positive results by meeting the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1...

Read More

September 11, 2023

0

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences ( NBIX ) announced positive top-line data from Phase 3 CAHtalystTM Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia ( CAH ) due...

Read More

September 12, 2023

0

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics ( ORTX ) - a global gene therapy firm, announced that the U.S. FDA has accepted the filing of its Biologics License Application ( BLA ) for OTL-200 in...

Read More

September 18, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 165
  • 166
  • 167
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy